HOOPER, LUNDY & BOOKMAN, P.C. for BRAINFUTURES
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; Issues related to medical adoption of and access to psychedelic drugs and therapies; S. 331 - HALT Fentanyl Act, provisions related to research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN New | SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) |
Medical/Disease Research/Clinical Labs MED
Issues related to a pathway for FDA approval of psychedelic drugs and therapies, issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; Issues related to medical adoption of and access to psychedelic drugs and therapies; S. 331 - HALT Fentanyl Act, provisions related to research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN New | SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.